News and Publications
This opinion piece from the CATO Institute grabbed our attention when it appeared in the public domain recently. Certainly, in the U.S. we have issues with the high cost of drugs and we realize that our healthcare system is overwhelmed trying to address many self-manageable conditions. The authors make a rational public health argument for nonprescription drug access to address these pressures when it comes to weight loss. The operational scenarios they suggest, however, do not include the elements of FDA’s rule for Nonprescription Access with an Additional Condition for Nonprescription Use, which is expected to be finalized shortly and which we imagine could add viability to the idea of nonprescription access to GLP-1 drug treatment. Thought Leaders are pioneering new frontiers for nonprescription access – public health, consumers, and industry all stand to benefit.
Defense Health Agency shifting towards a telehealth culture
Tracking the Impact of Health Intelligence Sharing Across the United States
Nonprescription Drug Product With an Additional Condition for Nonprescription Use
Consumer Healthcare stakeholders have developed expertise in digital marketing and digital commerce. The next frontier for CHC – taking shape in real-time – is Digital Care.
The Covid-19 pandemic brought healthcare to the forefront of the global conversation and made it an increasing priority for consumers – this offers a unique opportunity for industry development, particularly as we usher in a new era of technology-driven consumer healthcare. Engineered Self Care combines personalization with technology to meet evolving manufacturer, consumer and retailer needs.
The pipeline of medications that can be safely self-administered is extensive and exciting. The target populations for these medications are large and chronic. Industry can and must find a way forward to realize commercial gains and improve equity in public health outcomes.